Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docirbrutinib - Carna Biosciences

Next Previous
Drug Profile

Docirbrutinib - Carna Biosciences

Alternative Names: AS-1763; BN-102; CB-1763

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Carna Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • No development reported Diffuse large B cell lymphoma

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(In volunteers) in Netherlands (PO)
  • 13 Jun 2024 Preliminary efficacy, adverse events and pharmacokinetic data from a phase I in B-cell malignancies presented at the 29th Congress of the European Haematology Association (EHA-2024)
  • 09 Dec 2023 Pharmacodynamics data from a preclinical studies in Chronic lymphocytic leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top